New radioactive drug targets hard-to-treat cancers in early trial
NCT ID NCT07459283
First seen Mar 11, 2026 · Last updated May 22, 2026 · Updated 11 times
Summary
This early-phase trial tests a new radioactive drug (177Lu-INN805) in 10 adults with advanced solid tumors like head & neck, thyroid, lung, breast, or sarcoma cancer who have not responded to standard treatments. The drug is given every 6 weeks for up to 4 cycles to find the safest dose and check for side effects. The goal is to control tumor growth, not to cure the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Hospital of Jiangnan University
Wuxi, Jiangsu, China
Contact
Conditions
Explore the condition pages connected to this study.